Abstract:In psychiatric disorders, common and rare genetic variants cause widespread dysfunction of cells and their interactions, especially in the prefrontal cortex, giving rise to psychiatric symptoms. To better understand these processes, we traced the effects of common and rare genetics, and cumulative disease risk scores, to their molecular footprints in human cortical single-cell types. We demonstrated that examining gene expression at single-exon resolution is crucial for understanding the cortical dysregulation associated with diagnosis and genetic risk derived from common variants. We then used disease risk scores to identify a core set of genes that serve as a footprint of common and rare variants in the cortex. Pathways enriched in these genes included dopamine regulation, circadian entrainment, and hormone regulation. Single-nuclei-RNA-sequencing pinpointed these enriched genes to excitatory cortical neurons. This study highlights the importance of studying sub-gene-level genetic architecture to classify psychiatric disorders based on biology rather than symptomatology, to identify novel targets for treatment development. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Protocols <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3233860/pdf/jove-20-914.pdf> ### Funding Statement The Victorian Brain Bank tissue collection was supported by the National Health and Medical Research Council (NHMRC; Australia; grant number 566967) and the Cooperative Research Centre (CRC) for Mental Health and the Operational Infrastructure Support from the Victorian State Government. The New South Wales Brain Tissue Resource Centre at the University of Sydney was supported by the University of Sydney. Research reported in this publication was supported by the National Institute of Alcohol Abuse and Alcoholism of the National Institutes of Health under Award Number NIAAA012725-15. The content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health. Dr Knauer-Arloth was supported by the Brain Behaviour Research Foundation (NARSAD Young Investigator Grant, #28063). Dr Matosin was supported by an Al and Val Rosenstrauss Fellowship from the Rebecca L Cooper Medical Research Foundation and grants from the Brain Behaviour Research Foundation (NARSAD Young Investigator Grant, #26486) and the Rebecca L. Cooper Medical Research Foundation (#PG2020645). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethics committee/IRB of the Victorian Institute of Forensic Medicine gave ethical approval for this work. Ethics committee/IRB of the Human Ethics Committee of Melbourne Health gave ethical approval for this work. Ethics committee/IRB of the Central Institute of Mental Health Mannheim gave ethical approval for this work. Ethics committee/IRB of the University Hospital Bonn gave ethical approval for this work. Ethics committee/IRB of the Human Research Ethics Committees at the University of Wollongong gave ethical approval for this work. Ethics committee/IRB of the Ludwig-Maximilians-Universitaet Muenchen gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes Expression data of dataset 1 in the present study are available online at GEO (GSE208338) and the genotypes are available upon reasonable request to the authors. Genes altered by rare coding variants from SCHEMA exome sequencing results in dataset 2 are available online at https://schema.broadinstitute.org/downloads. snRNA-seq data of dataset 3 in the present study are available online at GEO (GSE205642). <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE205642> <https://drive.google.com/drive/folders/1JRyThjCwb7JFE6LdQQiAHwXQZFIO2o0V?usp=sharing> <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE208338> <https://schema.broadinstitute.org/downloads>

Impact of NPSR1 gene variation on the neural correlates of phasic and sustained fear in spider phobia – an imaging genetics and independent replication approach

Association between resting-state connectivity patterns in the defensive system network and treatment response in spider phobia—a replication approach

Altered Functional Coupling of the Bed Nucleus of the Stria Terminalis and Amygdala in Spider Phobic Fear

Neuropeptide S receptor gene variation modulates anterior cingulate cortex Glx levels during CCK-4 induced panic

Human-Specific Neuropeptide S Receptor Variants Regulate Fear Extinction in the Basal Amygdala of Male and Female Mice Depending on Threat Salience

The association between serotonin transporter availability and the neural correlates of fear bradycardia

Enhanced Discriminative Fear Learning of Phobia-Irrelevant Stimuli in Spider-Fearful Individuals

Inhibitory control and its modification in spider phobia – Study protocol for an antisaccade training trial

Toward a reliable detection of arachnophobia: subjective, behavioral, and neurophysiological measures of fear response

Cortical and Subcortical Brain Alterations in Specific Phobia and Its Animal and Blood-Injection-Injury Subtypes: A Mega-Analysis From the ENIGMA Anxiety Working Group

SpiDa-MRI, behavioral and (f)MRI data of adults with fear of spiders

Functional co-activation within the prefrontal cortex supports the maintenance of behavioural performance in fear-relevant situations before an iTBS modulated virtual reality challenge in participants with spider phobia

Variant-risk-exon interplay impacts circadian rhythm and dopamine signaling pathway in severe psychiatric disorders

Enhanced functional connectivity between sensorimotor and visual cortex predicts covariation bias in spider phobia

Neural response patterns in spider, blood-injection-injury and social fearful individuals: new insights from a simultaneous EEG/ECG–fMRI study

Orexin in the anxiety spectrum: association of a HCRTR1 polymorphism with panic disorder/agoraphobia, CBT treatment response and fear-related intermediate phenotypes

Neural mechanisms of automatic and direct processing of phobogenic stimuli in specific phobia

The fear of spiders: perceptual features assessed in augmented reality

Neuropeptide S Receptor variant (I107N) regulates behavioral characteristics and NPS effect in mice in a sex-dependent manner

Neural adaptation of cingulate and insular activity during delayed fear extinction: A replicable pattern across assessment sites and repeated measurements

Placebo effects in spider phobia: an eye-tracking experiment